CORVUS PHARMACEUTICALS, INC.

Analyst Reco. Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Delayed Nasdaq Other stock markets 08:22:48 29/04/2024 pm IST			5-day change	1st Jan Change
1.49 ^USD	+2.76%		+3.47%	-15.34%

09/04	Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	CI
20/03	Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating	20/03	MT
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating	11/23/11	MT
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating	07/23/07	MT
Oppenheimer Initiates Coverage on Corvus Pharmaceuticals With Outperform Rating, $7 Price Target	18/23/18	MT
Ladenburg Thalmann Adjusts Corvus Pharmaceuticals Price Target to $10 From $4, Maintains Buy Rating	30/23/30	MT
Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $4 From $2, Maintains Overweight Rating	09/23/09	MT
Ladenburg Thalmann Starts Corvus Pharmaceuticals at Buy with $2 Price Target	07/22/07	MT
Cantor Fitzgerald Adjusts Corvus Pharmaceuticals' Price Target to $4 from $8, Keeps Overweight Rating	09/22/09	MT
Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $8 From $5, Maintains Overweight Rating	03/21/03	MT
Jefferies Reinstates Corvus Pharmaceuticals at Buy With $8 Price Target	01/21/01	MT
CORVUS PHARMACEUTICALS : Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $5 From $10, Maintains Overweight Rating	03/21/03	MT
CORVUS PHARMACEUTICALS : Mizuho Securities Adjusts Corvus Pharmaceuticals' Price Target to $3.50 From $4, Maintains Neutral Rating	03/21/03	MT
CORVUS PHARMACEUTICALS : HC Wainwright Adjusts Corvus Pharmaceuticals' Price Target to $6 from $9.50, Keeps Buy Rating	16/21/16	MT
CORVUS PHARMACEUTICALS : Cantor Fitzgerald Starts Corvus Pharmaceuticals With Overweight Rating, $10 Price Target	27/21/27	MT
CORVUS PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Corvus Pharmaceuticals to $9.50 From $12, Maintains Buy Rating	26/21/26	MT
CORVUS PHARMACEUTICALS : Mizuho Downgrades Corvus Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $4 From $7	10/21/10	MT
CORVUS PHARMACEUTICALS : Wedbush Adjusts Price Target on Corvus Pharmaceuticals to $6 From $8, Keeps Outperform Rating	02/20/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer